Abstract
Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have